OPK vs LH

For growth investors, Labcorp Holdings Inc.

(LH) is the stronger pick with 7. 2% revenue growth year-over-year, versus -14. 9% for OPKO Health, Inc. (OPK). Labcorp Holdings Inc. (LH) offers the better valuation at 24. 7x trailing P/E (14. 5x forward), making it the more compelling value choice. Analysts rate OPKO Health, Inc. (OPK) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Labcorp Holdings Inc.

(LH) delivered a total return of +12. 6%, compared to -70. 5% for OPKO Health, Inc. (OPK). Over 10 years, the gap is even starker: LH returned +150. 7% versus OPK's -89. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Labcorp Holdings Inc.

(LH) is the lower-risk stock at 0. 52β versus OPKO Health, Inc. 's 1. 25β — meaning OPK is approximately 141% more volatile than LH relative to the S&P 500. On balance sheet safety, OPKO Health, Inc. (OPK) carries a lower debt/equity ratio of 34% versus 83% for Labcorp Holdings Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Labcorp Holdings Inc.

(LH) is pulling ahead at 7. 2% versus -14. 9% for OPKO Health, Inc. (OPK). On earnings-per-share growth, the picture is similar: Labcorp Holdings Inc. grew EPS 18. 3% year-over-year, compared to -291. 1% for OPKO Health, Inc.. Over a 3-year CAGR, LH leads at 5. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Labcorp Holdings Inc.

(LH) is the more profitable company, earning 6. 3% net margin versus -37. 2% for OPKO Health, Inc. — meaning it keeps 6. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LH leads at 10. 9% versus -36. 1% for OPK. At the gross margin level — before operating expenses — LH leads at 26. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for OPK: 156.

2% to $2. 87.

In this comparison, LH (1.

1% yield) pays a dividend. OPK does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Labcorp Holdings Inc.

(LH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 52), 1. 1% yield, +150. 7% 10Y return). Both have compounded well over 10 years (LH: +150. 7%, OPK: -89. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

LH pays a dividend while OPK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.